Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.

Clin Transl Gastroenterol · 2022 · PMC9132518 · PMID 35363628

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

Predictors of relapse (as defined earlier) were similar to those of treatment escalation (L3, SES-CD, pANCA positivity, and B2 being statistically significant ( P < 0.05) and L1, family history of IBD, and ASCA negativity being of borderline significance).

also in 2,624 other papers

a trend toward significanceno p-value reported

The simple endoscopic score for CD, L3 disease phenotype, and use of concomitant immunomodulators for at least the first 6 months revealed a trend toward significance on a univariate analysis.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.